Industry News

Cellceutix developing antibiotic compound for ocular infection

Cellceutix announced that it is currently conducting experiments on brilacidin, an antibiotic compound for the treatment of ophthalmic infections, including keratitis and conjunctivitis, according to a press release.

Prior studies have demonstrated the safety, tolerability and broad activity of brilacidin against gram-positive and gram-negative pathogens, including drug-sensitive and drug-resistant clinical isolate strains of ocular infections.

Also, previous pharmacokinetic studies showed that brilacidin has a high residence time on the surface of the eye with negligible systemic exposure, meaning that effective therapeutic concentrations of the antibiotic can be maintained in the eye with infrequent treatments, according to the release.

Cellceutix announced that it is currently conducting experiments on brilacidin, an antibiotic compound for the treatment of ophthalmic infections, including keratitis and conjunctivitis, according to a press release.

Prior studies have demonstrated the safety, tolerability and broad activity of brilacidin against gram-positive and gram-negative pathogens, including drug-sensitive and drug-resistant clinical isolate strains of ocular infections.

Also, previous pharmacokinetic studies showed that brilacidin has a high residence time on the surface of the eye with negligible systemic exposure, meaning that effective therapeutic concentrations of the antibiotic can be maintained in the eye with infrequent treatments, according to the release.